Cargando…

Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review)

Reduced expression in immortalized cells (REIC)/Dickkopf (Dkk)-3 is a tumor suppressor and therapeutic gene and has been studied with respect to the application of cancer gene therapy. Our previous studies demonstrated that the intratumoral injection of an adenovirus vector carrying the human REIC/D...

Descripción completa

Detalles Bibliográficos
Autores principales: WATANABE, MASAMI, NASU, YASUTOMO, KUMON, HIROMI
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919887/
https://www.ncbi.nlm.nih.gov/pubmed/24527065
http://dx.doi.org/10.3892/ol.2013.1777
_version_ 1782303102564564992
author WATANABE, MASAMI
NASU, YASUTOMO
KUMON, HIROMI
author_facet WATANABE, MASAMI
NASU, YASUTOMO
KUMON, HIROMI
author_sort WATANABE, MASAMI
collection PubMed
description Reduced expression in immortalized cells (REIC)/Dickkopf (Dkk)-3 is a tumor suppressor and therapeutic gene and has been studied with respect to the application of cancer gene therapy. Our previous studies demonstrated that the intratumoral injection of an adenovirus vector carrying the human REIC/Dkk-3 gene (Ad-REIC) suppresses tumor growth in mouse models of prostate, breast and testicular cancer and malignant mesothelioma. The mechanisms underlying these antitumor therapeutic effects have only been clarified recently. It has been demonstrated that Ad-REIC treatment inhibits cancer progression via the upregulation of systemic anticancer immunity. Under experimental conditions, autologous cancer vaccination via cancer-specific apoptosis and anticancer immune activation is a possible therapeutic mechanism. The robust anticancer effects observed in previous preclinical studies support the clinical utility of Ad-REIC. At present, a phase I–IIa study of Ad-REIC gene therapy in prostate cancer patients is ongoing. The current study reviews the observations of previous fundamental studies and summarizes the anticancer mechanisms of intratumoral Ad-REIC treatment in terms of cancer vaccination.
format Online
Article
Text
id pubmed-3919887
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-39198872014-02-13 Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review) WATANABE, MASAMI NASU, YASUTOMO KUMON, HIROMI Oncol Lett Articles Reduced expression in immortalized cells (REIC)/Dickkopf (Dkk)-3 is a tumor suppressor and therapeutic gene and has been studied with respect to the application of cancer gene therapy. Our previous studies demonstrated that the intratumoral injection of an adenovirus vector carrying the human REIC/Dkk-3 gene (Ad-REIC) suppresses tumor growth in mouse models of prostate, breast and testicular cancer and malignant mesothelioma. The mechanisms underlying these antitumor therapeutic effects have only been clarified recently. It has been demonstrated that Ad-REIC treatment inhibits cancer progression via the upregulation of systemic anticancer immunity. Under experimental conditions, autologous cancer vaccination via cancer-specific apoptosis and anticancer immune activation is a possible therapeutic mechanism. The robust anticancer effects observed in previous preclinical studies support the clinical utility of Ad-REIC. At present, a phase I–IIa study of Ad-REIC gene therapy in prostate cancer patients is ongoing. The current study reviews the observations of previous fundamental studies and summarizes the anticancer mechanisms of intratumoral Ad-REIC treatment in terms of cancer vaccination. D.A. Spandidos 2014-03 2013-12-27 /pmc/articles/PMC3919887/ /pubmed/24527065 http://dx.doi.org/10.3892/ol.2013.1777 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
WATANABE, MASAMI
NASU, YASUTOMO
KUMON, HIROMI
Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review)
title Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review)
title_full Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review)
title_fullStr Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review)
title_full_unstemmed Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review)
title_short Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review)
title_sort adenovirus-mediated reic/dkk-3 gene therapy: development of an autologous cancer vaccination therapy (review)
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919887/
https://www.ncbi.nlm.nih.gov/pubmed/24527065
http://dx.doi.org/10.3892/ol.2013.1777
work_keys_str_mv AT watanabemasami adenovirusmediatedreicdkk3genetherapydevelopmentofanautologouscancervaccinationtherapyreview
AT nasuyasutomo adenovirusmediatedreicdkk3genetherapydevelopmentofanautologouscancervaccinationtherapyreview
AT kumonhiromi adenovirusmediatedreicdkk3genetherapydevelopmentofanautologouscancervaccinationtherapyreview